186 related articles for article (PubMed ID: 32554434)
1. Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.
Cheong EJY; Nair PC; Neo RWY; Tu HT; Lin F; Chiong E; Esuvaranathan K; Fan H; Szmulewitz RZ; Peer CJ; Figg WD; Chai CLL; Miners JO; Chan ECY
J Pharmacol Exp Ther; 2020 Sep; 374(3):438-451. PubMed ID: 32554434
[TBL] [Abstract][Full Text] [Related]
2. CYP17A1-independent production of the neurosteroid-derived 5α-pregnan-3β,6α-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by Abiraterone.
de Mello Martins AGG; Allegretta G; Unteregger G; Haupenthal J; Eberhard J; Hoffmann M; van der Zee JA; Junker K; Stöckle M; Müller R; Hartmann RW; Ohlmann CH
J Steroid Biochem Mol Biol; 2017 Nov; 174():183-191. PubMed ID: 28890368
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
Attard G; Reid AH; Auchus RJ; Hughes BA; Cassidy AM; Thompson E; Oommen NB; Folkerd E; Dowsett M; Arlt W; de Bono JS
J Clin Endocrinol Metab; 2012 Feb; 97(2):507-16. PubMed ID: 22170708
[TBL] [Abstract][Full Text] [Related]
5. A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone.
Garrido M; Peng HM; Yoshimoto FK; Upadhyay SK; Bratoeff E; Auchus RJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():1-10. PubMed ID: 24508512
[TBL] [Abstract][Full Text] [Related]
6. Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1.
Petrunak EM; Rogers SA; Aubé J; Scott EE
Drug Metab Dispos; 2017 Jun; 45(6):635-645. PubMed ID: 28373265
[TBL] [Abstract][Full Text] [Related]
7. CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2.
Malikova J; Brixius-Anderko S; Udhane SS; Parween S; Dick B; Bernhardt R; Pandey AV
J Steroid Biochem Mol Biol; 2017 Nov; 174():192-200. PubMed ID: 28893623
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2.
Fehl C; Vogt CD; Yadav R; Li K; Scott EE; Aubé J
J Med Chem; 2018 Jun; 61(11):4946-4960. PubMed ID: 29792703
[TBL] [Abstract][Full Text] [Related]
9. [CYP17A1 inhibitors in prostate cancer: mechanisms of action independent of the androgenic pathway].
Audenet F; Murez T; Ripert T; Villers A; Neuzillet Y
Prog Urol; 2013 Oct; 23 Suppl 1():S9-15. PubMed ID: 24314739
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of the binding mode between cytochrome P450 17A1 and prostate cancer drugs in the absence of haem iron.
Song D; Zhang J; Wang Y; Hu J; Xu S; Xu Y; Shen H; Wen X; Sun Z
J Biomol Struct Dyn; 2019 Oct; 37(16):4161-4170. PubMed ID: 30431391
[TBL] [Abstract][Full Text] [Related]
11. Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site.
Petrunak EM; Bart AG; Peng HM; Auchus RJ; Scott EE
J Biol Chem; 2023 Mar; 299(3):102999. PubMed ID: 36773804
[TBL] [Abstract][Full Text] [Related]
12. Hedgehog Proteins Consume Steroidal CYP17A1 Antagonists: Potential Therapeutic Significance in Advanced Prostate Cancer.
Bordeau BM; Ciulla DA; Callahan BP
ChemMedChem; 2016 Sep; 11(18):1983-6. PubMed ID: 27435344
[TBL] [Abstract][Full Text] [Related]
13. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
[TBL] [Abstract][Full Text] [Related]
14. Limited in vitro efficacy of CYP17A1 inhibition on human castration resistant prostate cancer.
Kosaka T; Miyajima A; Yasumizu Y; Miyazaki Y; Kikuchi E; Oya M
Steroids; 2014 Dec; 92():39-44. PubMed ID: 25150014
[TBL] [Abstract][Full Text] [Related]
15. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
DeVore NM; Scott EE
Nature; 2012 Jan; 482(7383):116-9. PubMed ID: 22266943
[TBL] [Abstract][Full Text] [Related]
16. Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors.
Bonomo S; Hansen CH; Petrunak EM; Scott EE; Styrishave B; Jørgensen FS; Olsen L
Sci Rep; 2016 Jul; 6():29468. PubMed ID: 27406023
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Structure-Activity Relationships of Novel Non-Steroidal CYP17A1 Inhibitors as Potential Prostate Cancer Agents.
Wróbel TM; Rogova O; Sharma K; Rojas Velazquez MN; Pandey AV; Jørgensen FS; Arendrup FS; Andersen KL; Björkling F
Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204665
[TBL] [Abstract][Full Text] [Related]
18. Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer.
Toren PJ; Kim S; Pham S; Mangalji A; Adomat H; Guns ES; Zoubeidi A; Moore W; Gleave ME
Mol Cancer Ther; 2015 Jan; 14(1):59-69. PubMed ID: 25351916
[TBL] [Abstract][Full Text] [Related]
19. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
Bird IM; Abbott DH
J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency.
Fernández-Cancio M; Camats N; Flück CE; Zalewski A; Dick B; Frey BM; Monné R; Torán N; Audí L; Pandey AV
Pharmaceuticals (Basel); 2018 Apr; 11(2):. PubMed ID: 29710837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]